Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma.

doi:10.1073/pnas.1421601112

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma.

Proceedings of the National Academy of Sciences of the United States of America - 24 Feb 2015

Guillaumond Fabienne, Bidaut Ghislain, Ouaissi Mehdi, Servais Stéphane, Gouirand Victoire, Olivares Orianne, Lac Sophie, Borge Laurence, Roques Julie, Gayet Odile, Pinault Michelle, Guimaraes Cyrille, Nigri Jérémy, Loncle Céline, Lavaut Marie-Noëlle, Garcia Stéphane, Tailleux Anne, Staels Bart, Calvo Ezequiel, Tomasini Richard, Iovanna Juan Lucio, Vasseur Sophie

Abstract excerpt

The malignant progression of pancreatic ductal adenocarcinoma (PDAC) is accompanied by a profound desmoplasia, which forces proliferating tumor cells to metabolically adapt to this new microenvironment. We established the PDAC metabolic signature to highlight the main activated tumor metabolic pathways. Comparative transcriptomic analysis identified lipid-related metabolic pathways as being the most highly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Compartmentation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Extracellular Signal-Regulated MAP Kinases

Share to Gemcitabine

Share to Lipoproteins

Share to MAP Kinase Signaling System

Share to Metabolic Networks and Pathways

Share to Receptors, LDL

Source

Open in PubMed Open full text

Identifiers

PMID: 25675507
DOI: 10.1073/pnas.1421601112
PMCID: PMC4345573

Genes

LDLR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma.PMID 25675507Read ↗

Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets.Semantic proximity Read ↗

The complex landscape of pancreatic cancer metabolismSemantic proximity Read ↗

The biological role of metabolic reprogramming in pancreatic cancerSemantic proximity Read ↗

Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma ClassificationSemantic proximity Read ↗

Autophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic TumorsSemantic proximity Read ↗

Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modelingSemantic proximity Read ↗

The Intricate Metabolism of Pancreatic Cancers.Semantic proximity Read ↗

Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modelingSemantic proximity Read ↗

Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer.Semantic proximity Read ↗

Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance.Semantic proximity Read ↗

SREBP1 is associated with lipid-metabolic reprogramming and apoptotic regulation in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.